因特利亚制药

最新新闻

• Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  J.P. Morgan Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Announces Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• 评级变动
  Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• Tracking Cathie Wood: Added over 110,000 shares of gene-editing firm NTLA, while continuing to reduce holdings and optimize portfolio allocation.
  牛牛名人追蹤 · 2026/9/14
• H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), TriSalus Life Sciences (TLSI) and Fractyl Health, Inc. (GUTS)
  TipRanks · 2026/5/13
• 评级变动
  William Blair Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)
  TipRanks · 2026/5/14
• 评级变动
  A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $9 to $58
  \u5e02\u573a\u8d44\u8baf · 2026/4/29
• 评级变动
  A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $19 to $49
  \u5e02\u573a\u8d44\u8baf · 2026/6/16
• 评级变动
  TD Cowen Maintains Intellia Therapeutics(NTLA.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $49
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• 评级变动
  Evercore Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $24
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $29
  \u5e02\u573a\u8d44\u8baf · 2026/8/15
• 评级变动
  Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Sagimet Biosciences, Inc. Class A (SGMT)
  TipRanks · 2026/4/28
• 评级变动
  CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Wolfe Research Downgrades Intellia Therapeutics(NTLA.US) to Sell Rating, Announces Target Price $9
  \u5e02\u573a\u8d44\u8baf · 2026/7/16
• Wedbush Initiates Intellia Therapeutics(NTLA.US) With Hold Rating, Announces Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/7

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。